semaglutide 503b
How Will Pharmacies Adapt to Semaglutide Exclusion?
In 2024 the FDA announced it will exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, forcing pharmacies to redesign sourcing, shift to ready-to-use kits, and tighten compliance within weeks. The move eliminates a key shortcut for compounding GLP-1 weight-loss drugs and compels every pharmacy to audit its inventory